Free Daily Podcast Summary
Pharmaceutical Executive: Daily Summaries Delivered
by Pharmaceutical Executive Podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today2 min
Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case
In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, and C.K. Wang argues that high-quality real-world data represents the most promising path forward for closing persistent gaps in ovarian cancer care.
- Yesterday3 min
Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Collaboration
In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alnylam Pharmaceuticals and Inceptive Nucleics announce a three-year strategic AI collaboration worth up to $2 billion, and Anne Marie Robertson of Eversana speaks on the trends shaping the future of oncology commercialization following ASCO 2026.
- Yesterday35 min
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to offer a candid, expert-driven look at the pharmacy benefit manager (PBM) landscape, including the operational complexities confronting biopharma manufacturers and what these companies must understand to protect their revenue and expand patient access. Mendelsohn cuts through the spin to examine where PBM reform efforts are progressing and falling short, how payer vertical integration is compounding financial risk for manufacturers and why the onus increasingly falls on drugmakers themselves to police the data, the contracts and the dollars at stake.01:32 - PBM scrutiny: Where it’s missing the mark 05:54 - Pharma’s chief PBM concerns 08:08 - Formulary compliance and transparency12:00 - Data correlation and rebate accuracy18:00 - Addressing multipayer-claim complexity19:03 - Benefit-claim breakdowns: The 340B effect 20:14 - Why coordination issues persist 21:16 - Independent PBMs: Is their model game-changing?26:01 - PBM reform potential and pace29:09 - Future pressure points for manufacturers
- 2 days ago3 min
Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden
In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidian Therapeutics announce a global research collaboration worth up to $1.9 billion to develop RNA exon editors for inherited kidney diseases, and the FDA issues new draft guidance to reduce the submission burden for gene therapy developers.
- 3 days ago3 min
Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301
In today's Pharmaceutical Executive Daily, FDA has accepted a new drug application for giredestrant under priority review, FDA also issues a complete response letter for Cingulate's CTx-1301, and Dan Troy, former FDA Chief Counsel, explains the roadblocks and hurdles facing the FDA's efforts to bring stricter oversight to direct-to-consumer prescription drug advertising.
- 4 days ago3 min
Pharmaceutical Executive Daily: FDA Approves Xocova
In today's Pharmaceutical Executive Daily, the FDA approves Shionogi's Xocova, a pharma M&A roundup covers Servier's acquisition of Edgewise Therapeutics' muscular dystrophy, Eli Lilly's licensing of Hanmi's long-acting GLP-2 therapy, and the merger of Rallybio and Avenzo Therapeutics, finally Sean Werner examines why breakthrough cell and gene therapies continue to fail at the regulatory finish line.
- 1 weeks ago2 min
Pharmaceutical Executive Daily: WHO Identifies Priority Treatment Candidates for Ebola
In today’s Pharmaceutical Executive Daily, Harpreet Singh discusses the evolving regulatory landscape for biopharma, the World Health Organization identifies three priority treatment candidates for the Bundibugyo strain of Ebola virus disease, and this week’s pharma roundup highlights new findings on Mounjaro and long COVID-related immune system changes.
- 1 weeks ago2 min
Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.
About Pharmaceutical Executive
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Pharmaceutical Executive in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Pharmaceutical Executive daily summary?
It's a free AI-powered email that summarizes new episodes of Pharmaceutical Executive as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Pharmaceutical Executive podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Pharmaceutical Executive product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Pharmaceutical Executive Podcast.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Pharmaceutical Executive release new episodes?
Pharmaceutical Executive publishes daily. Our AI generates a summary within hours of each new episode.
What topics does Pharmaceutical Executive cover?
Pharmaceutical Executive covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Pharmaceutical Executive summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.